Industries > Pharma > Global Vaccines Sales Market Forecast 2019-2029

Back to Pharma Reports

Global Vaccines Sales Market Forecast 2019-2029

Name: Visiongain
Address: Airport House, Surrey, London, CR0 0XZ, United Kingdom
Telephone: +44 (0) 20 7549 9987

Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra

PUBLISHED: 25 June 2019

PAGES: 201

PRODUCT CODE: PHA0453

SUBMARKET: Pharma Therapeutic Drugs

SKU: PHA0453 Categories: Pharma, Pharma, Therapeutic Drugs Tags: PHA0453, PHA0456, PHA0477, PHA0521, PHA0550, PHA0554, PHA0725

The global vaccines market is estimated at $41bn in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period. The Paediatric Vaccines segment held 56% of the Global Vaccines market in 2018.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 201-page report you will receive 121 charts– all unavailable elsewhere.

The 201-page report provides clear detailed insight into the global vaccines sales market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Vaccines Sales Market forecasts from 2019-2029

• Global Vaccines Sales Market forecasts from 2019-2029 by Submarket:
• Paediatric Vaccines
• Adult Vaccines
• Elderly Vaccines
• Travel Vaccines
• Therapeutic Vaccines

• Global Vaccines Sales Market forecasts from 2019-2029 by Leading Vaccines:
• Prevnar
• Gardasil
• Fluzone
• Pentacel
• ProQuad
• Infanrix/Pediarix
• Zostavax
• RotaTeq
• Hepatitis Vaccines
• Menactra

• Global Vaccines Sales Market forecasts from 2019-2029 by Regional and National Market:
• US
• EU5: Germany, France, Italy, UK, Spain
• Japan
• Brazil
• Russia
• India
• China

• Profiles of the selected leading companies:
• AstraZeneca
• Eli Lilly
• Emergent BioSolutions Inc.
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co.
• Pfizer
• Sanofi
• Serum Indian Institute Pvt. Ltd.
• Takeda

• The Vaccines Market Pipeline Analysis

• A SWOT and STEP analysis of the global vaccines market

• Key Questions Answered by this Report:
• What is the current size of the overall global human vaccines market? How much will this market be worth from 2018 to 2029?
• What are the main drivers and restraints that will shape the overall vaccines market over the next ten years?
• What are the main segments within the overall human vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2028?
• How will political and regulatory forces influence regional markets?
• How will market shares of the leading national markets change by 2029, and which geographical region will lead the market in 2029?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are the leading vaccines? What are their revenues and latest developments?
• What are some of the most prominent human vaccines currently in development?
• What are the main trends that will affect the world vaccines market between 2018 and 2029?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global vaccines market evolve over the forecasted period, 2018 to 2029?
• How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Vaccines Sales Market. You find data, trends and predictions.

Buy our report today Global Vaccines Sales Market Forecast 2019-2029: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1. Report Overview

1.1 Overview of the World Vaccines Market

1.2 Why You Should Read This Report

1.3 How This Report Delivers

1.4 Main Questions Answered by This Analytical Study

1.5 Who is This Report For?

1.6 Methods of Research and Analysis

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2. Introduction to the World Human Vaccines Market

2.1 Human Vaccines - Aiming for Global Disease Prevention

2.2 What is the Social and Economic Burden?

2.3 Vaccine Technology

2.3.1 Inactivated Vaccines

2.3.2 Live Attenuated Vaccines

2.3.3 Conjugate Vaccines

2.3.4 Recombinant Vector Vaccines

2.4 Key Influencers of the Human Vaccine Market

2.4.1 Governments and International Organizations

2.4.1.1 The World Health Organisation (WHO)

2.4.1.2 The Governmental Influence

2.4.2 Leading Manufacturers

2.4.2.1 Merck& Co.

2.4.2.2 Sanofi

2.4.2.3 GlaxoSmithKline

2.4.2.4 Pfizer

2.5 Human World Vaccines – Market Segmentation

2.5.1 Paediatric Vaccines

2.5.2 Adult Vaccines

2.5.3 Elderly Vaccines

2.5.4 Travel Vaccines

2.5.5 Therapeutic Vaccines

3. World Vaccine Market Outlook, 2019-2029

3.1 World Vaccine Market, 2018

3.1.1 Paediatric Vaccines Maintains Constant Demand

3.1.2 Ageing Population Requires More Care

3.1.3 Emerging Markets Demand Better Immunity

3.2 The World Human Vaccines Forecast, 2019-2029

3.3 The World Vaccine Market: Industry Trends

3.3.1 Undulating Demand

3.3.2 Supply Restraints

3.3.3 Funding Trends

3.3.4 Protecting the Workforce of an Economy

4. World Vaccine Submarkets: Prospects, 2019-2029

4.1 Paediatric Vaccines

4.1.1 Paediatric Vaccine Forecast, 2019-2029

4.1.2 Paediatric Vaccine Trends

4.1.2.1 Innovative Delivery

4.1.2.2 Fear Factor

4.1.2.3 Novel Vectors

4.2 Adult Vaccines

4.2.1 Adult Vaccine Forecast, 2019-2029

4.2.2 Adult Vaccine Trends

4.2.2.1 Fighting the Flu

4.2.2.2 HPV

4.2.2.3 Repeat Doses for Continued Protection

4.3 Elderly Vaccines

4.3.1 Elderly Vaccine Forecast, 2019-2029

4.3.2 Elderly Vaccine Trends

4.3.2.1 With Age Comes Greater Risk

4.3.2.2 Ageing Population across the Globe

4.4 Travel Vaccines

4.4.1 Travel Vaccines Forecast, 2018-2029

4.4.2 Travel Vaccine Trends

4.4.2.1 Zika Virus Outbreak

4.4.2.2 Globalization Carries Diseases

4.5 Therapeutic Vaccines

4.5.1 Therapeutic Vaccine Trends

5. Leading Vaccines: Revenue Forecasts, 2019-2029

5.1 Prevnar (Pfizer) - Pneumococcal Pneumonia

5.2 Gardasil (Merck & Co.) - HPV

5.3 Fluzone (Sanofi) – Influenza

5.4 Pentacel (Sanofi) – DtaP, Polio, HiB

5.5 ProQuad / M-M-R II / Varivax (Merck and Co.) – Varicella/Chickenpox, Measles, Mumps, Rubella.

5.6 Infanrix/Pediarix (GSK) – Diptheria, Tetanus and Acellular Pertussis

5.7 Zostavax (Merck and Co.) – Herpes

5.8 RotaTeq (Merck and Co.) – Rotavirus

5.9 Hepatitis Vaccines (GSK) – Hepatitis A & B

5.10 Menactra (Sanofi) – Meningococcal

6. Regional and Leading Developed National Vaccines Markets, 2019-2029

6.1 North America Vaccine Market, 2019-2029

6.1.1 The US Vaccine Market, 2018

6.1.2 The US Vaccine Market Forecast, 2019-2029

6.2 Japanese Vaccine Market, 2019-2029

6.2.1 The Japanese Vaccine Market, 2018

6.2.2 The Japanese Vaccine Market Forecast, 2019-2029

6.2.3 Addressing the Alleged Vaccine Gap

6.3 EU5 Vaccine Market, 2019-2029

6.3.1 The EU5 Vaccine Market, 2018

6.3.2 The EU5 Vaccine Market Forecast, 2019-2029

6.4 United Kingdom Vaccine Market, 2019-2029

6.4.1 The UK Vaccine Market, 2018

6.4.2 The UK Vaccine Market Forecast, 2019-2029

6.5 France: Vaccine Market, 2019-2029

6.5.1 The French Vaccine Market, 2018

6.5.2 The French Vaccine Market Forecast, 2019-2029

6.5.3 French Healthcare System – Immunization Policy

6.6 Germany: Vaccine Market, 2019-2029

6.6.1 The German Vaccine Market, 2018

6.6.2 The German Vaccine Market Forecast, 2019-2029

6.7 Italy: Vaccine Market, 2019-2029

6.7.1 The Italian Vaccine Market, 2018

6.7.2 The Italian Vaccine Market Forecast, 2019-2029

6.7.3 Challenges in Public Healthcare

6.8 Spain: Vaccine Market, 2019-2029

6.8.1 The Spanish Vaccine Market, 2018

6.8.2 The Spanish Vaccine Market Forecast, 2019-2029

6.8.3 District Rules – Economic Challenges

7. Leading Emerging National Markets, 2019-2029

7.1 China: Vaccine Market, 2019-2029

7.1.1 The Chinese Vaccine Market, 2018

7.1.2 The Chinese Vaccine Market Forecast, 2019-2029

7.1.3 Setting-Up Domestic Vaccine Industries

7.2 India: Vaccine Market, 2019-2029

7.2.1 The Indian Vaccine Market, 2018

7.2.2 The Indian Vaccine Market Forecast, 2019-2029

7.2.3 The Extent to which the Vaccine Market Can Flourish?

7.3 Brazil: Vaccine Market, 2019-2029

7.3.1 The Brazilian Vaccine Market, 2018

7.3.2 The Brazilian Vaccine Market Forecast, 2019-2029

7.3.3 Zika Outbreak

7.4 Russia: Vaccine Market, 2019-2029

7.4.1 The Russian Vaccine Market, 2018

7.4.2 The Russian Vaccine Market Forecast, 2019-2029

7.4.3 Power of the State

8. Leading Manufacturers of Vaccines for Human Use

8.1 GlaxoSmithKline (GSK)

8.1.1 GSK Vaccine Performance

8.1.2 GSK Developments

8.1.2.1 Mergers and Acquisitions

8.1.2.2 GSK Vaccine Pipeline

8.2 Merck& Co.

8.2.1 Merck Vaccine Performance

8.2.2 Merck Developments

8.2.2.1 Merck Market Movements

8.2.2.2 Collaborations

8.2.2.3 Merck Pipeline

8.3 Sanofi

8.3.1 Sanofi Vaccine Performance

8.3.2 Sanofi Developments

8.3.2.1 Acquisitions & Expansions

8.3.2.2 Sanofi Vaccine Pipeline

8.4 Pfizer

8.4.1 Pfizer Vaccine Performance

8.4.1.1 Financial Overview

8.4.2 Pfizer Developments

8.4.2.1 Pfizer Mergers & Acquisitions

8.4.2.2 Pfizer Pipeline

8.5 Johnson & Johnson

8.5.1 Financial Overview

8.6 AstraZeneca

8.6.1 Financial Overview

8.7 Eli Lilly and Company

8.7.1 Eli Lilly and Company Vaccine Performance

8.7.1.1 Financial Overview

8.7.2 Eli Lilly and Company Developments

8.8 Takeda Pharmaceutical Company Limited

8.8.1 Takeda Pharmaceutical Company Limited Vaccine Performance

8.8.1.1 Financial Overview

8.9 Serum Institute of India Private Limited

8.9.1 Serum Institute of India Private Limited Vaccine Performance

8.10 Emergent BioSolutions Inc.

8.10.1 Emergent BioSolutions Inc. Vaccine Performance

8.11 Key Strategic Acquisitions and Collaborations

8.12 Other Companies Serving the Vaccines Market

9. Research & Development, 2018

9.1 Prophylactic Vaccines R&D Pipeline

9.1.1 Paediatric Vaccines R&D Pipeline

9.1.2 Adult Vaccines R&D Pipeline

9.1.3 Elderly Vaccines R&D Pipeline

9.1.4 Travel Vaccines R&D Pipeline

9.2 Therapeutic Vaccines R&D Pipeline

10. Qualitative Analysis of the World Vaccines Market

10.1 SWOT Analysis of the World Human Vaccines Market

10.1.1 Strengths

10.1.1.1 Ageing Population

10.1.1.2 Prevention is Better than Cure

10.1.1.3 Demand from Emerging Markets Continue

10.1.1.4 Promising R&D Pipeline

10.1.1.5 Increasing Awareness

10.1.2 Weaknesses

10.1.2.1 High Manufacturing Costs

10.1.2.2 Time Constraints

10.1.2.3 Barriers to Market Entry

10.1.3 Opportunities

10.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods

10.1.3.2 Shifting Focus on Adults Vaccines

10.1.4 Threats

10.1.4.1 Oligarchic Presence of Pharmaceutical Giants

10.1.4.2 Productivity Gap

10.2 STEP Analysis of the World Human Vaccines Industry and Market

10.2.1 Social Factors

10.2.1.1 Maintaining a Healthier Workforce

10.2.1.2 Public Hesitation - Fear of Unwanted Side-Effects

10.2.2 Technological Forces

10.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics

10.2.3 Economic Factors

10.2.3.1 High Costs of Production

10.2.3.2 Soaring Vaccines Demand from Developing Countries

10.2.4 Political Factors

10.2.4.1 Governments Play Crucial Roles in Vaccination

11. Conclusions

11.1 Segment Market Share Shift

11.2 Elderly People Become the New Target Market

11.3 Endemic Infections Drive Travel Vaccines Growth

11.4 Emerging Markets: High Demand for Vaccines

11.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth

11.6 Strong and Diverse Research and Development

11.7 Concluding Remarks

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 3.1 The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2019-2029

Table 4.1 World Vaccines Submarkets: Revenue Forecasts ($bn), AGR (%), CAGR (%), 2019-2029

Table 4.2 World Vaccines Submarkets: Market Shares (%), 2017-2029

Table 4.3 World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 4.4 World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 4.5 World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 4.6 World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.1 Prevnar Revenue ($bn), 2014-2017

Table 5.2 Prevnar Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.3 Gardasil Revenue ($bn), 2014-2017

Table 5.4 Gardasil Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.5 Fluzone/Vaxigrip: Revenue ($bn), 2014-2017

Table 5.6 Fluzone Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.7 Pentacel Revenue ($bn), 2014-2017

Table 5.8 Pentacel Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.9 ProQuad / M-M-R II / Varivax Revenue ($bn), 2014-2017

Table 5.10 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.11 Infanrix/Pediarix Revenue ($bn), 2014-2016

Table 5.12 Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.13 Zostavax Revenue ($bn), 2014-2017

Table 5.14 Zostavax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.15 RotaTeq Revenue ($bn), 2014-2017

Table 5.16 RotaTeq Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.17 GSK Hepatitis Vaccines Revenue ($bn), 2014-2016

Table 5.18 GSK Hepatitis Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029

Table 5.19 Menactra Revenue ($bn), 2014-2017

Table 5.20 Menactra Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029

Table 6.1 Leading National Market Revenue Forecasts ($bn), 2018, 2023, 2029

Table 6.2 Leading Developed National Markets Revenue Forecasts ($bn), 2018, 2023, 2029

Table 6.3 Leading Developed National Market Shares (%), 2018, 2023, 2029

Table 6.4 North America Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%) and CAGR (%), 2019-2029

Table 6.5 North America Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029

Table 6.6 The US Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029

Table 6.7 The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.8 Europe Vaccines Revenue Forecast by Submarkets ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.9 Europe Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2019-2029

Table 6.10 The EU5 Vaccines World Market Shares (%), 2018, 2023, 2029

Table 6.11 EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.12 The UK Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.13 The French Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.14 The German Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.15 The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.16 The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 7.1 Asia-Pacific Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 7.2 Asia-Pacific Vaccines Revenue Forecast, By Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029

Table 7.3 Leading Emerging National Market Revenue Forecasts ($bn), 2018, 2023, 2029

Table 7.4 Leading Emerging National Market Shares (%), 2018, 2023, 2029

Table 7.5 The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 7.6 The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029

Table 7.7 The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029

Table 7.8 The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share and CAGR (%), 2019-2029

Table 9.1 Prophylactic Vaccines in Development, 2018

Table 9.2 Paediatric Vaccines in Development, 2018

Table 9.3 Adult Vaccines in Development, 2018

Table 9.4 Elderly Vaccines in Development, 2018

Table 9.5 Travel Vaccines in Development, 2018

Table 9.6 Therapeutic Vaccines in Development, 2018

List of Figures

Figure 1.1 World Vaccines Market Segmentation, 2017

Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2018

Figure 3.2 World Vaccines Leading National Market Shares (%), 2018

Figure 3.3 World Vaccines Leading National Market Shares (%), 2023

Figure 3.4 World Vaccines Leading National Market Shares (%), 2029

Figure 3.5 World Vaccines Market: Drivers and Restraints

Figure 4.1 World Vaccines Submarket (%) Segmentation, 2018

Figure 4.2 World Paediatric Vaccines Market Share (%), 2019

Figure 4.3 World Paediatric Vaccines Market Share (%), 2023

Figure 4.4 World Paediatric Vaccines Market Share (%), 2029

Figure 4.5 World Paediatric Vaccines Revenue Forecast ($bn), 2019-2029

Figure 4.6 World Adult Vaccines Market Share (%), 2019

Figure 4.7 World Adult Vaccines Market Share (%), 2023

Figure 4.8 World Adult Vaccines Market Share (%), 2029

Figure 4.9 World Adult Vaccines Revenue Forecast ($bn), 2019-2029

Figure 4.10 World Elderly Vaccines Market Share (%), 2019

Figure 4.11 World Elderly Vaccines Market Share (%), 2023

Figure 4.12 World Elderly Vaccines Market Share (%), 2029

Figure 4.13 World Elderly Vaccines Revenue Forecast ($bn), 2019-2029

Figure 4.14 World Travel Vaccines Market Share (%), 2019

Figure 4.15 World Travel Vaccines Market Share (%), 2023

Figure 4.16 World Travel Vaccines Market Share (%), 2029

Figure 4.17 World Travel Vaccines Revenue Forecast ($bn), 2019-2029

Figure 5.1 Prevnar Revenue Forecast ($bn), 2019-2029

Figure 5.2 Gardasil Revenue Forecast ($bn), 2019-2029

Figure 5.3 Fluzone Revenue Forecast ($bn), 2019-2029

Figure 5.4 Pentacel Revenue Forecast ($bn), 2019-2029

Figure 5.5 ProQuad / M-M-R II / VarivaxRevenue Forecast ($bn), 2019-2029

Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), 2019-2029

Figure 5.7 Zostavax Revenue Forecast ($bn), 2019-2029

Figure 5.8 RotaTeq Revenue Forecast ($bn), 2019-2029

Figure 5.9 GSK Hepatitis Vaccines Revenue Forecast ($bn), 2019-2029

Figure 5.10 Menactra Revenue Forecast ($bn), 2019-2029

Figure 6.1 The US Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.2 The Japanese Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.3 EU5 Vaccines Market Share (%), 2018

Figure 6.4 EU5 Vaccines Market Share (%), 2023

Figure 6.5 EU5 Vaccines Market Share (%), 2029

Figure 6.6 The UK Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.7 The French Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.8 The German Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.9 The Italian Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.10 The Spanish Vaccines Revenue Forecast ($bn), 2019-2029

Figure 7.1 BRIC Countries Vaccines Market Share (%), 2018

Figure 7.2 BRIC Countries: Vaccines Market Share (%), 2023

Figure 7.3 BRIC Countries: Vaccines Market Share (%), 2029

Figure 7.4 The Chinese Vaccines Revenue Forecast ($bn), 2019-2029

Figure 7.5 The Indian Vaccines Revenue Forecast ($bn), 2019-2029

Figure 7.6 The Brazilian Vaccines Revenue Forecast ($bn), 2019-2029

Figure 7.7 The Russian Vaccines Revenue Forecast ($bn), 2019-2029

Figure 8.1 GSK Vaccines Revenue ($bn), 2015-2017

Figure 8.2 GSK Vaccines Region Breakdown (%), 2017

Figure 8.3 Merck Vaccines Revenue (%), 2017

Figure 8.4 Sanofi Vaccines Revenue ($bn), 2014-2017

Figure 8.5 Pfizer Revenue ($bn), 2014-2017

Figure 8.6 J&J Revenue ($bn), 2014-2017

Figure 8.7 AstraZeneca Revenue ($bn), 2014-2017

Figure 8.8 Eli Lilly and Company Revenue ($bn), 2014-2017

Figure 8.9 Takeda Pharmaceutical Revenue ($bn), 2014-2017

Figure 10.1 SWOT Analysis of the World Vaccines Market

Figure 10.2 STEP Analysis of the World Vaccines Market

Figure 11.1 World Paediatric Vaccines Revenue Forecast ($bn), 2018-2029

Figure 11.2 World Elderly Vaccines Revenue Forecast ($bn), 2018-2029

Figure 11.3 Asia-Pacific Vaccines Revenue Forecast (% Share), 2018-2029

AstraZeneca

Bavarian Nordic

Bayer

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL)

Binnopharm

BiondVax

Bristol-Myers Squibb

Chemo-Sero-Therapeutic Research Institute

China National Biotec Group

Denka Seiken

Eli Lilly

Emergent BioSolutions Inc

Fresenius

GlaxoSmithKline (GSK)

GlaxoWellcome

Henogen

Immatics

InterveXion Therapeutics

Johnson & Johnson

LigoCyte

MedImmune

Merck & Co.

Merck Sharp & Dohme Corp

Nanolek

NewLink Genetics

Okairos

PaxVax

Pfizer

Protein Science

Roche

Sanofi Pasteur

Serum Indian Institute Pvt. Ltd.

SmithKline Beecham

Takeda

Themis Bioscience

Organizations Mentioned in the Report

Centers for Disease Control and Protection (CDC)

Centre for Biologics Evaluation and Research (CBER)

Developing Countries Vaccine Manufacturers Network (DCVMN)

European Medicines Agency (EMA)

Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

Food and Drug Administration (FDA)

Global Alliance for Vaccines

Global Alliance for Vaccines and Immunization (GAVI)

International Financing Facility for Immunisation

National Health Service (NHS)

Pan American Health Organization (PAHO)

The Butantan Institute

The Indian Department of Biotech

The Ministry of Health, Labour and Welfare and the Health Service Bureau

UNICEF

World Health Organization (WHO)

Download sample pages

Complete the form below to download your free sample pages for Global Vaccines Sales Market Forecast 2019-2029

Download sample pages

Complete the form below to download your free sample pages for Global Vaccines Sales Market Forecast 2019-2029

Case studies

Need customized work?

Report overview

Methodology

Reports catalogue

Would you like to get the latest Visiongain pharma reports catalogue?

What are the dynamic growth sectors? where are the regional business opportunities?

Which technologies will prevail and who are the leading companies succeeding in these sectors and why?

If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.

If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987

Forthcoming reports

Human Microbiome Therapeutics Market 2019-2029
Top 20 Urology Companies 2019
Global Antidepressant and Anti-Anxiety Drugs Market Forecasts 2019-2029
The Top 100 In-Vitro Diagnostics Companies to Watch 2019
Global Hypertension Drugs Market 2019-2029
The Next Generation Sequencing Market 2019-2029
Lyophilisation for Pharmaceuticals: Products and Services 2019-2029
Top 25 In Vitro Diagnostics (IVD) Companies 2019
Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2019-2029
Global Biomarkets and Technologies Market 2019-2029

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Kuwait Pharmaceutical Association
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Generic Medicines Association
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Free Visiongain Report

Connect with us

Visiongain Pharma

Latest Pharma news

“Global Vaccine Contract Manufacturing market set to grow to $3,831.7m by 2025” says new Visiongain report

Major fluctuations in demand are seen in the case of influenza, as was seen during pandemics over the last decade. Unexpectedly, the Coronavirus or COVID-19 outbreak that started from Wuhan, China, has spread across continents, affecting various industries globally.

08 April 2020

READ

Visiongain’s analysis indicates that total revenue on Tuberculosis Treatment Drugs Market will be $1,080 million in 2020 due to the World Health Organization strong commitment towards ending TB leading to increase in funding for the research and development both in developed as well and under-developed markets

Due to maturity of generic drug market, companies are moving away from generics drug into therapeutic market by building strong portfolio for development of anti-tuberculosis drug emphasizing all types of TB cases.

06 April 2020

READ

The Global Wound Care Market Is Set to Boom, Particularly in Emerging Economies

The global wound care market is big, and only set to grow bigger. Currently, estimates show a CAGR of 4.6% in the years to come, with the overall market growing from US$19.8 billion in 2019 to US$24.8 billion by 2024. The industry is ripe with opportunity, with that growth coming from several factors – but most especially growth in emerging …

30 March 2020

READ

“The global nasal drug delivery technology market is estimated to have reached $44,385 million in 2019” says new Visiongain report

Nasal Sprays segment held the largest market share of the global nasal drug delivery technology market in 2019.

30 March 2020

READ

Industries > Pharma > Global Vaccines Sales Market Forecast 2019-2029

Back to Pharma Reports

Global Vaccines Sales Market Forecast 2019-2029

Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra

Download sample pages

Related reports

Indian Pharmaceutical Market Forecast 2019-2029

Drug Delivery Technologies Market Forecast 2019-2029

Global Stem Cell Technologies and Applications Market 2019-2029

Global Precision Medicine Market Forecast 2019-2029

Cholera Vaccines Market Report 2019-2029

Lyophilization in Pharmaceutical Market Forecast 2019-2029

Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029

Biologics Market Trends and Forecasts 2019-2029

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029

Pharma Leader Series: Top 30 Ophthalmic Drug Manufacturers 2019-2029

Download sample pages

Connect with us

Latest Pharma news

“Global Vaccine Contract Manufacturing market set to grow to $3,831.7m by 2025” says new Visiongain report

The Global Wound Care Market Is Set to Boom, Particularly in Emerging Economies

“The global nasal drug delivery technology market is estimated to have reached $44,385 million in 2019” says new Visiongain report

Categories

Our Clients

Do you have any custom requirements I can help you with?

Any specific country/segment/company ? Email us today.

Any specific country/segment/company ?
Email us today.